P53 Antagonist Shows Early Activity in Advanced Liposarcoma

(MedPage Today) -- CHICAGO--Almost 90% of patients with metastatic liposarcoma achieved disease control with an investigational drug targeting p53 suppression, according to an early study reported at the American Society of Clinical Oncology...